Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection
Open Access
- 30 October 2014
- journal article
- research article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 62 (3), 533-540
- https://doi.org/10.1016/j.jhep.2014.10.035
Abstract
No abstract availableFunding Information
- Janssen Pharmaceuticals
- Merck
- Gilead Sciences
- Roche
- Gilead UK and Ireland Corporate Contributions
- Novartis
- British Microcirculation Society
- GlaxoSmithKline
This publication has 25 references indexed in Scilit:
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- Mechanism for Effective Lymphoid Cell and Tissue Loading Following Oral Administration of Nucleotide Prodrug GS-7340Molecular Pharmaceutics, 2012
- Renal tubular dysfunction during long‐term adefovir or tenofovir therapy in chronic hepatitis BAlimentary Pharmacology & Therapeutics, 2012
- Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrationsAIDS, 2010
- Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical TrialThe Journal of Infectious Diseases, 2010
- Tenofovir‐associated renal and bone toxicityHIV Medicine, 2009
- Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis BNew England Journal of Medicine, 2008
- Chronic Administration of Tenofovir to Rhesus Macaques from Infancy through Adulthood and Pregnancy: Summary of Pharmacokinetics and Biological and Virological EffectsAntimicrobial Agents and Chemotherapy, 2008
- Risk and Predictors of Mortality Associated With Chronic Hepatitis B InfectionClinical Gastroenterology and Hepatology, 2007
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976